The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) […]
With stressors mounting daily on the health care system due to the COVID-19 pandemic, a de-prioritization of the childbearing family has been noted. Their care has […]
Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting […]
UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling (IFN). The team found […]